169 related articles for article (PubMed ID: 34539667)
21. Immune suppression in premalignant respiratory papillomas: enriched functional CD4+Foxp3+ regulatory T cells and PD-1/PD-L1/L2 expression.
Hatam LJ; Devoti JA; Rosenthal DW; Lam F; Abramson AL; Steinberg BM; Bonagura VR
Clin Cancer Res; 2012 Apr; 18(7):1925-35. PubMed ID: 22322668
[TBL] [Abstract][Full Text] [Related]
22. Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors.
Kilinc MO; Aulakh KS; Nair RE; Jones SA; Alard P; Kosiewicz MM; Egilmez NK
J Immunol; 2006 Nov; 177(10):6962-73. PubMed ID: 17082611
[TBL] [Abstract][Full Text] [Related]
23. Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer.
Bastman JJ; Serracino HS; Zhu Y; Koenig MR; Mateescu V; Sams SB; Davies KD; Raeburn CD; McIntyre RC; Haugen BR; French JD
J Clin Endocrinol Metab; 2016 Jul; 101(7):2863-73. PubMed ID: 27045886
[TBL] [Abstract][Full Text] [Related]
24. In-vitro effect of pembrolizumab on different T regulatory cell subsets.
Toor SM; Syed Khaja AS; Alkurd I; Elkord E
Clin Exp Immunol; 2018 Feb; 191(2):189-197. PubMed ID: 28963773
[TBL] [Abstract][Full Text] [Related]
25. Programmed Cell Death Ligand (PD-L)-1 Contributes to the Regulation of CD4
de Freitas E Silva R; Gálvez RI; Pereira VRA; de Brito MEF; Choy SL; Lotter H; Bosurgi L; Jacobs T
Front Immunol; 2020; 11():574491. PubMed ID: 33193363
[TBL] [Abstract][Full Text] [Related]
26. Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapy.
Kim PS; Jochems C; Grenga I; Donahue RN; Tsang KY; Gulley JL; Schlom J; Farsaci B
J Immunol; 2014 Mar; 192(6):2622-33. PubMed ID: 24516200
[TBL] [Abstract][Full Text] [Related]
27. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies.
Kumagai S; Togashi Y; Kamada T; Sugiyama E; Nishinakamura H; Takeuchi Y; Vitaly K; Itahashi K; Maeda Y; Matsui S; Shibahara T; Yamashita Y; Irie T; Tsuge A; Fukuoka S; Kawazoe A; Udagawa H; Kirita K; Aokage K; Ishii G; Kuwata T; Nakama K; Kawazu M; Ueno T; Yamazaki N; Goto K; Tsuboi M; Mano H; Doi T; Shitara K; Nishikawa H
Nat Immunol; 2020 Nov; 21(11):1346-1358. PubMed ID: 32868929
[TBL] [Abstract][Full Text] [Related]
28. [Lymphocyte activation markers in patients with ovarian cancer].
Nowicka A; Rogala E; Bednarek W; Barczyński B; Wertel I; Piekarczyk W; Kotarski J
Ginekol Pol; 2012 Oct; 83(10):737-43. PubMed ID: 23383558
[TBL] [Abstract][Full Text] [Related]
29. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
[TBL] [Abstract][Full Text] [Related]
30. Phenotypic and functional characteristics of CD4+ CD39+ FOXP3+ and CD4+ CD39+ FOXP3neg T-cell subsets in cancer patients.
Schuler PJ; Schilling B; Harasymczuk M; Hoffmann TK; Johnson J; Lang S; Whiteside TL
Eur J Immunol; 2012 Jul; 42(7):1876-85. PubMed ID: 22585562
[TBL] [Abstract][Full Text] [Related]
31. Analysis of the PD-1/PD-L1 axis in human autoimmune thyroid disease: Insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity.
Álvarez-Sierra D; Marín-Sánchez A; Ruiz-Blázquez P; de Jesús Gil C; Iglesias-Felip C; González Ó; Casteras A; Costa RF; Nuciforo P; Colobran R; Pujol-Borrell R
J Autoimmun; 2019 Sep; 103():102285. PubMed ID: 31182340
[TBL] [Abstract][Full Text] [Related]
32. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.
Sugiyama D; Nishikawa H; Maeda Y; Nishioka M; Tanemura A; Katayama I; Ezoe S; Kanakura Y; Sato E; Fukumori Y; Karbach J; Jäger E; Sakaguchi S
Proc Natl Acad Sci U S A; 2013 Oct; 110(44):17945-50. PubMed ID: 24127572
[TBL] [Abstract][Full Text] [Related]
33. Effector Antitumor and Regulatory T Cell Responses Influence the Development of Nonmelanoma Skin Cancer in Kidney Transplant Patients.
Crespo E; Fernandez L; Lúcia M; Melilli E; Lauzurica R; Penin RM; Quer A; Luque S; Quero M; Manonelles A; Torras J; Cruzado JM; Cañas L; Grinyó JM; Bestard O
Transplantation; 2017 Sep; 101(9):2102-2110. PubMed ID: 28403126
[TBL] [Abstract][Full Text] [Related]
34. The PDL1-PD1 axis converts human TH1 cells into regulatory T cells.
Amarnath S; Mangus CW; Wang JC; Wei F; He A; Kapoor V; Foley JE; Massey PR; Felizardo TC; Riley JL; Levine BL; June CH; Medin JA; Fowler DH
Sci Transl Med; 2011 Nov; 3(111):111ra120. PubMed ID: 22133721
[TBL] [Abstract][Full Text] [Related]
35. An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinoma.
Tang Y; Xu X; Guo S; Zhang C; Tang Y; Tian Y; Ni B; Lu B; Wang H
PLoS One; 2014; 9(3):e91551. PubMed ID: 24637664
[TBL] [Abstract][Full Text] [Related]
36. Immune phenotype of patients with stage IV metastatic inflammatory breast cancer.
Fernandez SV; MacFarlane AW; Jillab M; Arisi MF; Yearley J; Annamalai L; Gong Y; Cai KQ; Alpaugh RK; Cristofanilli M; Campbell KS
Breast Cancer Res; 2020 Dec; 22(1):134. PubMed ID: 33267869
[TBL] [Abstract][Full Text] [Related]
37. GITR ligation enhances functionality of tumor-infiltrating T cells in hepatocellular carcinoma.
van Beek AA; Zhou G; Doukas M; Boor PPC; Noordam L; Mancham S; Campos Carrascosa L; van der Heide-Mulder M; Polak WG; Ijzermans JNM; Pan Q; Heirman C; Mahne A; Bucktrout SL; Bruno MJ; Sprengers D; Kwekkeboom J
Int J Cancer; 2019 Aug; 145(4):1111-1124. PubMed ID: 30719701
[TBL] [Abstract][Full Text] [Related]
38. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
39. Increased liver-infiltrating CD8+FoxP3+ regulatory T cells are associated with tumor stage in hepatocellular carcinoma patients.
Yang ZQ; Yang ZY; Zhang LD; Ping-Bie ; Wang SG; Ma KS; Li XW; Dong JH
Hum Immunol; 2010 Dec; 71(12):1180-6. PubMed ID: 20870003
[TBL] [Abstract][Full Text] [Related]
40. Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas.
Attig S; Hennenlotter J; Pawelec G; Klein G; Koch SD; Pircher H; Feyerabend S; Wernet D; Stenzl A; Rammensee HG; Gouttefangeas C
Cancer Res; 2009 Nov; 69(21):8412-9. PubMed ID: 19843860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
